H igh arterial stiffness is increasingly conceptualized as a cause of hypertension, in addition to being a consequence of long-standing high blood pressure.
Methods
The Framingham Heart Study enrolled a sample of individuals from the community of Framingham, Massachusetts, in 1948. In 1971, the children of the Original cohort and their spouses were enrolled in the Offspring cohort, 12 and in 2002, the study was expanded by enrolling a sample of the children of the Offspring cohort (grandchildren of the Original cohort), that is, the third-generation cohort. 13 For the present investigation, we included participants from the thirdgeneration cohort who attended their first examination cycle (eligible n=4095) and who had both parents enrolled in the offspring cohort (n=2878). A further requirement was that both parents attended the offspring examination cycle 7, when parental hypertension status was determined and arterial stiffness measurements made (n=1895). Participants from the third-generation cohort with prevalent hypertension (n=259), prevalent cardiovascular disease (CVD; n=5), missing values of at least 1 tonometry measure (n=61), or missing values of other variables (n=6) were not included, leaving 1564 eligible thirdgeneration individuals for the primary analyses in this investigation (Table S1 in the online-only Data Supplement shows characteristics of included and excluded individuals, respectively).
The Boston University Medical Center Institutional Review Board approved the study protocol, and all participants provided written informed consent before participating.
Arterial Tonometry Measures and Definition of Hypertension
During offspring examination cycle 7 (1998-2001 ; mean age, 62 years) and third-generation examination cycle 1 (2002-2005 ; mean age, 38 years), all participants underwent applanation tonometry according to standardized protocol. At the same examinations, blood pressure values (mean of 2 measurements) were obtained on the left arm using a mercury column sphygmomanometer after the participant had been seated for at least 5 minutes. We defined hypertension as use of antihypertensive medications or having a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg. MAP was calculated as (systolic blood pressure+2*diastolic blood pressure)/3.
All tonometry measurements (for partial correlation coefficients between the measurements, see Table S2 ) were undertaken with the participant supine after 5 to 10 minutes of rest.
14 Waveforms were stored digitally and analyzed in a core laboratory (Cardiovascular Engineering, Inc, Norwood, MA) by investigators blinded to clinical information. 14 The forward pressure wave amplitude was defined as the difference between pressure at the waveform foot and pressure at the peak of the pressure waveform or at the first systolic inflection point measured in the carotid artery.
14 Augmentation index was calculated as the difference between first systolic inflection point and peak waveform (ie, the augmentation pressure) divided by the total pulse pressure and multiplied by 100. Carotid-femoral pulse wave velocity was measured as the length between the carotid and femoral measurement sites, adjusted for parallel transmission, and divided by the time delay between the foot of the carotid and femoral waveforms. 15 In accordance with previous reports from our group, 2 carotid-femoral pulse wave velocity was inverse-transformed and multiplied by −1000 to reduce heteroscedasticity and to restore directionality of associations.
Statistical Methods
We assessed the relations between parental hypertension (determined at their seventh examination cycle) and offspring arterial stiffness indices (determined at their first examination cycle [thirdgeneration cohort]) using multivariable generalized estimating equations with adjustment for familial structure. 16 We used the offspring arterial stiffness measures as dependent variables and included parental hypertension as an independent, categorical variable (0, 1, or 2 parents with hypertension). Correlation among siblings was accounted for with an exchangeable correlation matrix in all regression models. We also investigated the odds ratios of belonging to the upper sex-specific quartile of the different arterial stiffness measures according to parental hypertension status (0, 1 or 2, as noted above) and also according to whether or not at least 1 parent also belonged to the upper quartile of the same stiffness measure using multivariable logistic regression using generalized estimating equations. In this latter analysis, we also included offspring with prevalent hypertension (to avoid exclusion of the most informative individuals). Because many individuals from the offspring cohort received antihypertensive medications, we focused on augmentation index and carotid-femoral pulse wave velocity as outcomes in these analyses. All models were performed in 2 steps. Initially, we adjusted for sex, height, and age. Subsequently, we additionally adjusted for weight, total:high-density lipoprotein cholesterol ratio, triglyceride concentrations, use of cholesterol-lowering medication, diabetes mellitus, and smoking (all covariates known to influence vascular stiffness measures in our previous reports). 14, 17 Models of carotid-femoral pulse wave velocity and forward pressure wave amplitude were additionally adjusted for mean arterial blood pressure values, and models of augmentation index and carotid-femoral pulse wave velocity were additionally adjusted for heart rate. 14, 17 G.F.M. and R.S.V. had full access to the data and take responsibility for the accuracy and integrity of the analyses.
Results
A total of 468, 715, and 381 individuals had 0, 1, and 2 parents with hypertension, respectively. Our sample comprised younger-to middle-aged individuals, with a slight female predominance. The prevalence of risk factors for hypertension and CVD was overall low (Table 1) .
Age-and sex-adjusted mean levels of arterial stiffness measures by parental hypertension status are presented in the Figure. Adjusting for age, sex, and height, we observed greater mean arterial blood pressure, forward pressure wave amplitude, augmentation index, and carotid-femoral pulse wave velocity in the offspring for every additional parent with hypertension (Table 2 ). On adjustment for multiple risk factors, the observed associations between parental hypertension status and mean arterial blood pressure and forward pressure wave amplitude remained highly statistically significant, whereas associations with carotid-femoral pulse wave velocity and augmentation index were attenuated (Table 2) . Similarly, the odds ratios of belonging to the upper quartile of MAP, forward pressure wave amplitude, and augmentation index were significantly increased for offspring whose parents had hypertension, with multivariable-adjusted estimates that ranged between 1.80 for augmentation index and 2.60 for MAP (Table 2) . Results were similar for maternal versus paternal hypertension (Table  S3) . Estimates for other variables in the different models are presented in Table S4 .
We also investigated the relations between parental and offspring arterial stiffness measures in the total sample of individuals with and without clinical hypertension (n=1845; out of 4095 individuals from the third generation, totally 2042 were excluded because of only 1 parent in the study or missing parental tonometry measures [this number was different from main sample because fewer tonometry measures were analyzed], 11 were excluded because of prevalent CVD, 89 were eliminated because of missing tonometry measures, and additionally 8 were removed because of missing covariates). After multivariable adjustment, having at least 1 parent in the upper quartile of augmentation index and carotid-femoral pulse wave velocity, respectively, was associated with higher mean values and greater odds ratios of belonging to the upper quartile of the corresponding variable among offspring (Table 3) .
Discussion
In our study of young-to middle-aged, nonhypertensive individuals, we observed greater arterial stiffness in offspring of hypertensive parents compared with offspring of nonhypertensive parents. Our observations are consistent with the concept that higher arterial stiffness is involved in the pathogenesis of hypertension. 2 Our observations also confirmed the familial clustering of higher arterial stiffness, with individuals having 30% to 50% higher odds ratios of belonging to the upper quartile of augmentation index and carotid-femoral pulse wave velocity if at least one of their parents also were in the upper quartile of the distribution of the corresponding arterial stiffness measure.
Of the 4 indices evaluated, we observed the strongest association between parental hypertension and offspring MAP in our investigation. This was expected because MAP plays an important role in blood pressure elevation in young adults, and both measures are defined from actual blood pressure values. Furthermore, hypertension is the joint result of several contributing factors, and these different aspects of hypertension risk are likely to be reflected in MAP values (eg, risk mediated by components of high arterial stiffness, neurohumoral activity, low-grade inflammation, etc). For instance, we have previously shown that higher aortic stiffness, assessed as primary wave amplitude or carotid-femoral pulse wave velocity, is associated with microvascular dysfunction, which may contribute to elevation of MAP. 18 Elevation of MAP will have a direct and proportional effect on blood pressure. In addition, as a consequence of aortic diameter remodeling, primary wave amplitude is known to fall with age in young adults before midlife, which may have weakened the association between primary wave amplitude and hypertension in the third-generation cohort. Furthermore, only part of primary wave amplitude contributes to higher systolic blood pressure; the remainder reduces diastolic blood pressure and widens pulse pressure. In contrast, other tonometry measures may not capture all these aspects. In agreement hereto, we observed a somewhat less strong association between parental hypertension and tonometry measures (for instance, odds ratios of belonging to the upper quartile of the corresponding measures were 2.52, 2.36, and 2.11 for forward pressure wave amplitude, augmentation index, and carotid-femoral pulse wave velocity, respectively, compared with 3.11 for MAP, if 2 parents had hypertension in age-, sex-, and height-adjusted models). For all 4 indices, multivariable adjustment attenuated the associations. Whereas associations remained highly statistically significant for MAP and forward pressure wave amplitude, they became statistically nonsignificant for carotid-femoral pulse wave velocity and the augmentation index. Compared with MAP and the primary wave, carotid-femoral pulse wave velocity and augmentation index have a larger number of clinical correlates that may potentially mediate the association with parental hypertension. For example, carotid-femoral pulse wave velocity, but not the forward pressure wave amplitude, has been reported to correlate with several lipid-related variables including use of lipid-lowering medications, triglyceride concentrations, and high-density lipoprotein:total cholesterol ratio in the Framingham offspring cohort. 17 Both the forward pressure wave amplitude and carotid-femoral pulse wave velocity are measures reflective of arterial wall stiffness and aortic Estimates are compared with reference of having 0 parents with hypertension. Odds ratios refer to the odds ratio of belonging to the upper quartile of the respective variable. Multivariable analyses were adjusted for sex, height, weight, total:HDL cholesterol ratio, triglycerides, use of cholesterol-lowering medication, diabetes mellitus, and smoking. Multivariable models of CFPWV and forward pressure wave amplitude were additionally adjusted for mean arterial blood pressure values, and models of augmentation index and CFPWV additionally for heart rate. P values for trends obtained from sex-, age-, and height-adjusted models. Upper quartile reference values were >89 and >94 mm Hg for MAP among women and men; >44.6 and 50.7 mm Hg among women and men for forward pressure wave amplitude; >16.8% and >10.7% for augmentation index among women and men; and >6.7 and >7.6 m/s for women and men for CFPWV. CFPWV indicates carotid-femoral pulse wave velocity; HDL, high-density lipoprotein; and MAP, mean arterial pressure. *P<0.001. †P<0.01. ‡P<0.05. Linear regression models represent expected change in tonometry variable for offspring with a parent in quartile 4 versus offspring with parents in quartiles 1-3. Total sample size included third-generation participants with and without hypertension (n=1845). Multivariable analyses were adjusted for sex, height, weight, total:HDL cholesterol ratio, triglycerides, use of cholesterol-lowering medication, diabetes mellitus, and smoking. Multivariable models of CFPWV were additionally adjusted for mean arterial blood pressure values, and models of augmentation index additionally for heart rate. Upper quartile reference values were >16.8% and >10.7% for augmentation index among women and men, and >6.7 and >7.6 m/s for women and men for CFPWV. Upper quartile reference values were >27.8% and >18.8% for augmentation index among mothers and fathers, and >11. 3 diameter, but the forward pressure wave amplitude is more strongly related to aortic diameter than is carotid-femoral pulse wave velocity. 17 Additional studies are required to determine whether anatomic differences or unmeasured risk factors may explain the differential strength of association observed between carotid-femoral pulse wave velocity and forward pressure wave amplitude in relation to parental hypertension status. A possible explanation for the weakened association of carotid-femoral pulse wave velocity with parental hypertension compared with augmentation index may also relate to the fact that carotid-femoral pulse wave velocity increases rather later in life (ie, at a later age than the mean of our study sample).
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Genetic Evidence Linking Hypertension With Arterial Stiffness
Although our study suggests that high arterial stiffness and hypertension cluster within families, the underlying common genetic pathways remain to be elucidated. [20] [21] [22] Several genome-wide association studies have been performed to delineate the genetic determinants of blood pressure, and ≈280 single-nucleotide peptides have been reported to be associated with systolic blood pressure values. [23] [24] [25] [26] [27] [28] [29] [30] With regard to carotid-femoral pulse wave velocity, one meta-analysis of genome-wide association data of ≈21 000 individuals has been published to date. 20 It yielded significant associations related to a gene desert at chromosome 14 and suggestive loci on chromosomes 3 and 8. 20 An early effort was also undertaken in the Framingham 100K project to analyze the relation between blood pressure values, carotid-femoral pulse wave velocity, and forward pressure wave amplitude with genome-wide single-nucleotide peptides, but none of the investigated singlenucleotide peptides attained genome-wide significance level. 21 It is likely that larger sample sizes and focused searches are needed to reveal common genetic pathways linking arterial stiffness with hypertension.
Strengths and Limitations
The unique familial structure of the Framingham Heart Study enabled us to evaluate data on a large sample of individuals and their parents. In contrast to many other studies, we had actual data on parental hypertension status and did not rely on self-reported family history of high blood pressure. Additionally, the availability of tonometry measures in 2 generations using the same measurement protocol facilitated the evaluation of familial clustering of arterial stiffness measures.
There are, however, several limitations of our investigation that must be considered. The cross-sectional observational design precludes any causal inferences about parental hypertension status and offspring vascular stiffness. It remains, therefore, to be investigated whether increases in arterial stiffness in normotensive, young adults may serve as a good risk marker for incident hypertension in the future, a premise that we did not evaluate. Another limitation is that our study sample comprised relatively healthy young-to middle-aged community-dwelling white individuals of European ancestry, limiting the generalizability of our observations to other age groups and ethnicities.
Conclusions, Clinical Implications, and Perspectives
Among nonhypertensive, young-to middle-aged adults, parental hypertension is associated with greater arterial stiffness indices, including carotid-femoral pulse wave velocity, augmentation index, and forward pressure wave amplitude. The observed association may potentially reflect a subclinical precursor of future high blood pressure, a premise that warrants examination in future investigations. Furthermore, the usefulness of arterial tonometry measures for risk stratification (for hypertension risk) and the clinical consequences of high arterial stiffness in a familial setting merit further investigation. Recently, higher forward pressure wave amplitude has been reported as a risk factor for incident CVD even after adjustment for traditional risk factors in the Framingham Heart Study Offspring cohort. 31 Linking our observations to this previous report raises the possibility that individuals with parental hypertension may be a high-risk group that could be targeted aggressively with nonpharmacological means to prevent both future hypertension and CVD.
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